The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of prognostic characteristics between vintage and novel androgen receptor-axis-targeted drug among Japanese patients with non-metastatic castration-resistant prostate cancer: A multi-institutional study of Japanese Urological Oncology Group (JUOG).
 
Shinichi Sakamoto
No Relationships to Disclose
 
Kodai Sato
No Relationships to Disclose
 
Takahiro Kimura
No Relationships to Disclose
 
Yasuyuki Matsui
No Relationships to Disclose
 
Yusuke Shiraishi
No Relationships to Disclose
 
Kohei Hashimoto
No Relationships to Disclose
 
Hideaki Miyake
No Relationships to Disclose
 
Shintaro Narita
No Relationships to Disclose
 
Jun Miki
No Relationships to Disclose
 
Naotaka Nishiyama
No Relationships to Disclose
 
Tomohiko Ichikawa
No Relationships to Disclose
 
Hiroshi Kitamura
Honoraria - Astellas Pharma; AstraZeneca/Daiichi Sankyo; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Merck/Pfizer; MSD; Nippon Kayaku; Nippon Shinyaku; Sanofi; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/Daiichi Sankyo; Chugai Pharma; Eisai; Janssen; Kissei Pharmaceutical; MSD; Pfizer; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca/Daiichi Sankyo (Inst); Bayer Yakuhin (Inst); MSD (Inst); Sanofi (Inst); Takeda (Inst)